Evidence-based articles for the informed patient and caregiver - bridging the gap between PubMed abstracts and actionable knowledge. No false hope, no despair. Clear-eyed precision.
No immunotherapy is currently FDA-approved specifically for glioblastoma, but a growing number of clinical trials are open. Which ones you can enter depends heavily on your tumor's molecular profile - and knowing which markers matter can change the conversation with your oncologist.
Getting insurance pre-approval and an Indian Medical Visa before traveling for GBM treatment are two parallel processes that typically take four to six weeks and determine whether your treatment starts on schedule or stalls at the paperwork stage.
Most standard vitamins are generally safe alongside temozolomide, but a smaller group of herbal supplements carry documented interaction risks. This evidence-based guide explains which compounds show early promise in GBM research and which ones require an urgent conversation with your oncology team.
5-ALA fluorescence-guided surgery makes glioblastoma cells glow pink-red under blue-violet light, helping surgeons remove nearly twice as much tumor compared to standard white-light resection. Here is what the clinical evidence shows and what to ask your surgical team before the operation is scheduled.
Drug repurposing - adapting existing approved medicines for glioblastoma - is one of the most active areas of brain tumor research. This article explains which drugs are being studied, what the evidence actually shows, and how to prepare for a productive conversation with your oncologist.
When a glioblastoma sits near speech or motor areas, awake craniotomy allows real-time brain mapping to protect critical functions during resection. Learn how it compares to surgery under general anesthesia and what peer-reviewed evidence shows about neurological and survival outcomes.
Your glioblastoma pathology report contains molecular markers - IDH status, MGMT methylation, TERT mutation - that directly influence your treatment plan. This guide explains each marker in plain language so you can ask sharper questions before treatment begins.
Pediatric glioblastoma is biologically distinct from adult GBM, with different molecular drivers and weaker evidence for standard chemotherapy. This guide explains what those differences mean for treatment and how caregivers can access expert molecular review.
Glioblastoma fatigue is more than tiredness - it is a documented physiological symptom with multiple causes. Learn why it happens during GBM treatment and what the current evidence says about managing it.
The 15-month median survival figure attached to a glioblastoma diagnosis describes a population average, not your outcome. Learn which molecular and clinical factors actually shape individual prognosis - and how to act on that information from the first weeks after diagnosis.